CN110709104A - 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法 - Google Patents

用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法 Download PDF

Info

Publication number
CN110709104A
CN110709104A CN201880037918.XA CN201880037918A CN110709104A CN 110709104 A CN110709104 A CN 110709104A CN 201880037918 A CN201880037918 A CN 201880037918A CN 110709104 A CN110709104 A CN 110709104A
Authority
CN
China
Prior art keywords
aplnr
antibody
antagonist
antigen
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880037918.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·曹
E·舍昂
I·B·洛博夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN110709104A publication Critical patent/CN110709104A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880037918.XA 2017-05-06 2018-05-04 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法 Pending CN110709104A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
US62/502,621 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (1)

Publication Number Publication Date
CN110709104A true CN110709104A (zh) 2020-01-17

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880037918.XA Pending CN110709104A (zh) 2017-05-06 2018-05-04 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法

Country Status (9)

Country Link
EP (1) EP3618876A1 (OSRAM)
JP (1) JP7161494B2 (OSRAM)
KR (1) KR102667021B1 (OSRAM)
CN (1) CN110709104A (OSRAM)
AU (1) AU2018266324B2 (OSRAM)
EA (1) EA201992630A1 (OSRAM)
IL (1) IL270267B2 (OSRAM)
MX (1) MX389729B (OSRAM)
WO (1) WO2018208625A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12149266B2 (en) 2020-05-11 2024-11-19 Ascava, Inc. Exploiting locality of prime data for efficient retrieval of data that has been losslessly reduced using a prime data sieve
CN115920057A (zh) * 2023-01-03 2023-04-07 中国科学院合肥物质科学研究院 靶向aplnr蛋白棕榈酰化修饰的多肽及其在癌痛治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150252107A1 (en) * 2013-11-20 2015-09-10 Regeneron Pharmaceuticals, Inc. APLNR Modulators and Uses Thereof
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US20170096479A1 (en) * 2015-09-23 2017-04-06 Genentech, Inc. Optimized variants of anti-vegf antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9156911B2 (en) * 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
WO2013153049A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JP2017516490A (ja) 2014-03-20 2017-06-22 セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク（シーエヌアールエス） 癌を治療するためのアペリン／ａｐｊ／ｇｐ１３０シグナル伝達を阻害する化合物の使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
US20150252107A1 (en) * 2013-11-20 2015-09-10 Regeneron Pharmaceuticals, Inc. APLNR Modulators and Uses Thereof
CN105916881A (zh) * 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US20170096479A1 (en) * 2015-09-23 2017-04-06 Genentech, Inc. Optimized variants of anti-vegf antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIA ELEFTHERIADOU: "Long-term outcomes of aflibercept treatment for neovascular age-related macular", 《AMERICAN JOURNAL OF OPHTHALMOLOGY》 *

Also Published As

Publication number Publication date
AU2018266324A1 (en) 2019-11-28
IL270267A (OSRAM) 2019-12-31
KR102667021B1 (ko) 2024-05-21
AU2018266324B2 (en) 2024-02-01
KR20200004366A (ko) 2020-01-13
EA201992630A1 (ru) 2020-04-29
MX389729B (es) 2025-03-20
JP7161494B2 (ja) 2022-10-26
WO2018208625A1 (en) 2018-11-15
EP3618876A1 (en) 2020-03-11
MX2019012985A (es) 2020-01-13
IL270267B2 (en) 2024-06-01
JP2020518641A (ja) 2020-06-25
IL270267B1 (en) 2024-02-01
CA3062418A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US20230020514A1 (en) Methods for treating or preventing migraine headache
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US11104730B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
JP7161494B2 (ja) Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法
CA3062418C (en) Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
AU2023285108A1 (en) Anti-igf-1r antibody compositions
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
CN116368151A (zh) 抗-sema3a抗体及其用于治疗视网膜血栓栓塞性疾病的用途
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination